EGFR and non-small cell lung carcinoma: Another retrospective Japanese study recruiting 205 stage IV NSCLC patients under EGFR-TKIs treatment suggested that patients with NLR lower than 3.55 had longer PFS and OS compared with those with NLR higher than 3.55 (for PFS: HR = 1.82, P value <0.0001; for OS: HR = 1.78, P value <0.001) [6].